Rafferty Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Rafferty Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$707K	Sell	18,075 -19,601	-52%	-$605K	﹤0.01%	837
2026 Q1	$1.02M	Sell	37,676 -5,423	-13%	-$182K	﹤0.01%	766
2025 Q4	$1.85M	Buy	43,099 +29,421	+215%	+$1.11M	0.01%	663
2025 Q3	$387K	Sell	13,678 -4,620	-25%	-$138K	﹤0.01%	941
2025 Q2	$343K	Sell	18,298 -3,099	-14%	-$58.8K	﹤0.01%	956
2025 Q1	$385K	Buy	+21,397	New	+$434K	﹤0.01%	916
2022 Q3	–	Sell	-108,854	Closed	-$1.23M	–	1230
2022 Q2	$1.23M	Buy	108,854 +74,031	+213%	+$1.49M	0.01%	584
2022 Q1	$1.04M	Sell	34,823 -13,806	-28%	-$374K	0.01%	772
2021 Q4	$1.29M	Buy	48,629 +19,079	+65%	+$576K	0.01%	785
2021 Q3	$1.07M	Sell	29,550 -11,658	-28%	-$459K	0.01%	795
2021 Q2	$1.79M	Sell	41,208 -21,335	-34%	-$805K	0.01%	719
2021 Q1	$2.14M	Buy	62,543 +53,637	+602%	+$2.12M	0.01%	603
2020 Q4	$312K	Sell	8,906 -18,167	-67%	-$526K	﹤0.01%	799
2020 Q3	$650K	Buy	+27,073	New	+$665K	0.01%	647
2019 Q3	–	Sell	-28,317	Closed	-$739K	–	838
2019 Q2	$739K	Sell	28,317 -6,853	-19%	-$155K	0.01%	617
2019 Q1	$904K	Buy	+35,170	New	+$804K	0.01%	571

Other funds holding RIGL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rafferty Asset Management's RIGL Position: Q2 2026 in Review

Rafferty Asset Management reduced its Rigel Pharmaceuticals (RIGL) stake by 52% in Q2 2026, selling an estimated $605K and leaving 18,075 shares worth $707K. The position accounts for ﹤0.01% of the portfolio, ranked #837.

Rafferty Asset Management first reported a position in RIGL in Q1 2019 and has held it in 16 quarters since. The position peaked at $2.14M in Q1 2021. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

Rafferty Asset Management held 18,075 shares of Rigel Pharmaceuticals worth $707K as of Q2 2026.
Rafferty Asset Management sold 19,601 Rigel Pharmaceuticals shares in Q2 2026, an estimated $605K.
Rigel Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #837 holding.
Rafferty Asset Management first reported a position in Rigel Pharmaceuticals in Q1 2019 and has held it in 16 quarters since.
Rafferty Asset Management's Rigel Pharmaceuticals position peaked at $2.14M in Q1 2021.
156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.